Metformin-based chronotherapy can disrupt BMAL1–CLOCK–PER1–HK2 axis, thereby affecting glycolysis oscillation to overcome trastuzumab resistance in HER2-positive advanced gastric cancer. Here, ERBB2 is linked to gastric cancer.